Canine insulinoma has historically been associated with a poor prognosis; however, prolonged survival times have recently been reported. Prognostic indicators that are available preoperatively are of limited predictive accuracy, and consensus on post-operative treatment recommendations is lacking. The objectives of this study were to describe outcomes in dogs with insulinoma treated surgically, and to assess whether selected potential risk factors are strongly associated with outcomes after surgery. Medical records of two institutions were searched for dogs with insulinoma that were treated surgically. Forty-nine dogs were included. Thirty-nine dogs (80%) had immediate resolution of hypoglycaemia and 10 (20%) remained persistently hypoglycaemic postoperatively. The median survival time (MST) for all dogs was 561 days. The MST for dogs that had resolution of hypoglycaemia was 746 days. The median of the overall euglycaemic time (times from surgery to first detection of hypoglycaemia at any time point after surgery) for all dogs was 424 days. Forty-four percent of those that had resolution of hypoglycaemia experienced recurrence of hypoglycaemia by 2 years postoperatively. Pathological stage was a predictor of persistent post-operative hypoglycaemia which, in turn, was a predictor of survival time. These results show that dogs with insulinoma can have prolonged survival, and that pathological stage is a predictor of outcome.

中文翻译：

---

49例犬胰岛素瘤手术治疗结果

犬胰岛素瘤历来与预后不良有关。然而，最近报道了延长的生存时间。术前可用的预后指标的预测准确性有限，并且缺乏对术后治疗建议的共识。本研究的目的是描述手术治疗的胰岛素瘤犬的结果，并评估选定的潜在危险因素是否与手术后的结果密切相关。搜索了两个机构的医疗记录，寻找手术治疗的患有胰岛素瘤的狗。包括四十九只狗。39 只狗 (80%) 的低血糖立即消退，10 只 (20%) 的狗在术后持续低血糖。所有狗的中位生存时间 (MST) 为 561 天。患有低血糖症的狗的 MST 为 746 天。所有狗的总体血糖正常时间（从手术到手术后任何时间点首次检测到低血糖的时间）的中位数为 424 天。44% 的低血糖得到缓解的患者在术后 2 年出现低血糖复发。病理分期是术后持续低血糖的预测因子，而低血糖又是生存时间的预测因子。这些结果表明，患有胰岛素瘤的狗可以延长生存期，而病理阶段是结果的预测因素。44% 的低血糖得到缓解的患者在术后 2 年出现低血糖复发。病理分期是术后持续低血糖的预测因子，而低血糖又是生存时间的预测因子。这些结果表明，患有胰岛素瘤的狗可以延长生存期，而病理阶段是结果的预测因素。44% 的低血糖得到缓解的患者在术后 2 年出现低血糖复发。病理分期是术后持续低血糖的预测因子，而低血糖又是生存时间的预测因子。这些结果表明，患有胰岛素瘤的狗可以延长生存期，而病理阶段是结果的预测因素。